51 terminated. 51 Phase 2, 11 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 51 | Terminated 51 |
| Phase 1 | 11 | Terminated 11 |
| Phase 3 | 2 | Terminated 2 |
Follow Bladder Cancer: new trials by email Literature Review of Bladder Cancer trials Research Report on Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intervention of Bladder Cancer by CAR-T 4SCAR-PSMA, 4SCAR-FRa - Bladder Cancer, Urothelial Carcinoma Bladder | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2025-08-01 | 2026-08-24 |
| 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors - Cervical Cancer, Colorectal Cancer | Phase 2 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 11 | 2023-06-06 | 2025-07-10 |
| LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors Lerapolturev, 5% DDM - Solid Tumor, Bladder Cancer | Phase 1 / Phase 2 | Terminated | Istari Oncology, Inc. | 4 | 2021-08-01 | 2024-10-24 |
| Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors Tovorafenib - Melanoma, Solid Tumor | Phase 2 | Terminated | Day One Biopharmaceuticals, Inc. | 23 | 2021-07-15 | 2025-10-02 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab Trilaciclib, Gemcitabine, Cisplatin - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Terminated | G1 Therapeutics, Inc. | 92 | 2021-06-04 | 2025-09-08 |
| Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy Olaparib, Durvalumab - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Terminated | Latin American Cooperative Oncology Group | 140 | 2021-03-01 | 2021-06-16 |
| Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Seribantumab - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 2 | Terminated | Elevation Oncology | 54 | 2020-09-29 | 2025-04-03 |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers OC-001, Drug: OC-001 in Combination with Avelumab - Cancer, Neoplasms | Phase 1 / Phase 2 | Terminated | Ocellaris Pharma, Inc. | 73 | 2020-09-24 | 2026-01-12 |
| A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4. - Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer | Phase 1 / Phase 2 | Terminated | Genmab | 48 | 2020-07-15 | 2023-07-25 |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) Atezolizumab, Enfortumab Vedotin, Niraparib - Urothelial Carcinoma, Bladder Cancer | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 272 | 2019-06-01 | 2026-08-03 |
| Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA] - Oncology, Solid Tumor | Phase 1 / Phase 2 | Terminated | 4D pharma plc | 63 | 2019-01-10 | 2023-06-01 |
| A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer Avelumab - Bladder Cancer, Metastatic Bladder Cancer | Phase 1 / Phase 2 | Terminated | Baylor College of Medicine | 1 | 2018-12-14 | 2020-08-24 |
| Avelumab and Radiation in Muscle-Invasive Bladder Cancer Avelumab, Radiation - Bladder Cancer, Muscle Invasive Bladder Cancer | Phase 2 | Terminated | Dana-Farber Cancer Institute | 14 | 2018-12-13 | 2025-10-31 |
| Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners Memory structuring intervention + Vagal breathing, support and attention (usual care) - Colorectal Cancer, Bladder Cancer | Phase 2 | Terminated | Centre Oscar Lambret | 19 | 2018-07-25 | 2026-03-13 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Rucaparib - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Terminated | pharmaand GmbH | 97 | 2018-06-01 | 2023-06-09 |
| Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1 Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging - Bladder Cancer | Phase 2 | Terminated | Lawrence Fong | 4 | 2017-03-07 | 2020-01-21 |
| Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder Durvalumab, Cystoscopy with Biopsy - Carcinoma in Situ of Bladder, Bladder Cancer | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 17 | 2017-02-16 | 2022-07-29 |
| Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma nab-paclitaxel, Gemcitabine - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Terminated | SCRI Development Innovations, LLC | 3 | 2017-01-12 | 2023-12-05 |
| Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants Atezolizumab, Bacille Calmette-Guérin - Bladder Cancer | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 24 | 2016-06-13 | 2021-10-28 |
| Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) Pembrolizumab, Pembrolizumab/vibostolimab coformulation, Favezelimab/pembrolizumab coformulation - Bladder Cancer | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 296 | 2016-02-10 | 2026-08-31 |
Showing 20 of 51. Sign in to see all of them.
Urinary Bladder Neoplasms (51) · Carcinoma, Transitional Cell (9) · Carcinoma, Non-Small-Cell Lung (6) · Neoplasms (6) · Colorectal Neoplasms (5) · Neoplasm Metastasis (4) · Non-Muscle Invasive Bladder Neoplasms (4) · Uterine Cervical Neoplasms (4) · Breast Neoplasms (3) · Esophageal Neoplasms (3) · Kidney Neoplasms (3) · Melanoma (3) · Prostatic Neoplasms (3) · Sarcoma (3) · Squamous Cell Carcinoma of Head and Neck (3)
Female Urogenital Diseases (51) · Female Urogenital Diseases and Pregnancy Complications (51) · Male Urogenital Diseases (51) · Neoplasms by Site (51) · Urogenital Diseases (51) · Urologic Diseases (51) · Urologic Neoplasms (51) · Urinary Bladder Diseases (50) · Urogenital Neoplasms (50) · Neoplasms (45) · Neoplasms by Histologic Type (20) · Carcinoma (19) · Neoplasms, Glandular and Epithelial (19) · Digestive System Diseases (7) · Digestive System Neoplasms (7)
Gemcitabine (14) · Cisplatin (9) · avelumab (4) · Doxorubicin (3) · Methotrexate (3) · Paclitaxel (3) · Vinblastine (3) · Albumin-Bound Paclitaxel (2) · BCG Vaccine (2) · Carboplatin (2) · Radiotherapy (2) · Sorafenib (2) · Sunitinib (2) · atezolizumab (2) · durvalumab (2)
Memorial Sloan Kettering Cancer Center (3) · University of Michigan Rogel Cancer Center (3) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Hoffmann-La Roche (2) · Medical University of South Carolina (2) · Merck Sharp & Dohme LLC (2) · National Cancer Institute (NCI) (2) · SWOG Cancer Research Network (2) · 4D pharma plc (1) · Association of Urologic Oncology (AUO) (1) · Baylor College of Medicine (1) · Brown University (1) · CG Oncology, Inc. (1) · Celldex Therapeutics (1) · Centre Oscar Lambret (1)
United States (36) · France (6) · Spain (6) · Germany (4) · South Korea (4) · Canada (3) · United Kingdom (3) · Australia (2) · Greece (2) · Italy (2) · Japan (2) · Netherlands (2) · Belgium (1) · Brazil (1) · China (1)
Dean Bajorin, MD (2) · Gustavo Leone (2) · Ajjai S. Alva, M.D. (1) · Alex W Yeung, MBBS (1) · Alexander Karl, MD (1) · Andrew S. Kraft, MD (1) · Arlene Siefker-Radtke, MD (1) · Cora N. Sternberg, MD, FACP (1) · Daniel P. Petrylak, MD (1) · Derek Raghavan, MD, PhD, FRACP, FACP (1) · Edward E. Messing, MD (1) · Gary Steinberg, MD (1)
PMID 18568488, PMID 24249435, PMID 24318901, PMID 26370220, PMID 34030643, PMID 34051177, PMID 36803840, PMID 37651261, PMID 38740030, PMID 41428976, PMID 42826365
U10CA032102 (2), 2005 (1), 2009 (1), 2014 (1), 2017 (1), 2019 (1)